



Final – For Immediate Release

Symic Bio Appoints Matrix Biology Researcher and Professor Glenn Prestwich as Executive Vice President of Chemistry

SAN FRANCISCO, July 5 – Symic Bio, a biopharmaceutical company developing novel matrix regulator therapeutics, announced today the appointment of Glenn Prestwich, Ph.D., as Executive Vice President of Chemistry. Dr. Prestwich, Presidential Professor of Medicinal Chemistry at the University of Utah and former member of the Symic Bio Scientific Advisory Board, will assume a direct executive role in the advancement of the company’s platform of clinical-stage therapeutics and in the expansion of its pipeline.

“Glenn has helped pave the way in building industrial applications from increasing knowledge of extracellular matrix biology,” said Ken Horne, Symic Bio’s Chief Executive Officer. “His long experience in the field will help us develop new disease targeting opportunities and accelerate our therapeutics through clinical development. We are proud to have an individual with such a highly distinguished background as an integral member of our senior management team.”

“When I became aware of the opportunity to deepen my involvement with Symic, I leapt at the chance,” said Dr. Prestwich. “Not only has the company already demonstrated the broad potential of its matrix regulator technology, but in a relatively short period it has brought two programs through mid-stage clinical development. I have been greatly impressed by the company’s progress and look forward with excitement to realizing a shared vision of matrix biology applications.”

Dr. Prestwich has led translational research efforts as Special Presidential Assistant for Faculty Entrepreneurism and has served as Director of the Center for Cell Signaling and of the Center for Therapeutic Biomaterials at the University of Utah. He has authored over 650 publications and holds 38 patents. Dr. Prestwich has helped launch over nine life science companies and has advised numerous companies. He is an elected Fellow of the National Academy of Inventors and is the recipient of multiple awards, including the Utah Governor’s Medal for Science and Technology, the Rooster Prize of the International Society for Hyaluronan Science, the Volwiler Research Award, the University of Utah Distinguished Scholarly and Creative Research Award and the University of Utah Distinguished Innovation and Impact Award. Dr. Prestwich received his Ph.D. in Organic Chemistry from Stanford University.

About Symic Bio

Symic Bio is a biopharmaceutical company developing novel matrix regulators, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which is

targeting the prevention of peripheral vein graft failure, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

Investor Contact

Gitanjali Jain Ogawa
The Trout Group
(646) 378-2949
gogawa@troutgroup.com

Media Contacts

David Schull or Rich Allan
Russo Partners, LLC
(212) 845-4271
(646) 942-5588
david.schull@russopartnersllc.com
rich.allan@russopartnersllc.com